Savings

ORACEA® (OR-RAY-SHA) (doxycycline, USP) Capsule Delivers Visible Results

The patients pictured were actual participants in the rosacea treatment clinical trials for ORACEA®.
Individual results may vary.

PATIENT ID#: 301.115

In this clinical trial, many study subjects demonstrated improvements in their rosacea over course of the study, and approximately 30% were clear or almost clear of disease symptoms by the end of the study.

This study was a Phase III, parallel-group, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of ORACEA®, in which patients received
40 mg of ORACEA® or a placebo for 16 weeks.

view larger
*For insured patients only. Certain limitations apply. Click here for program details.
Important Safety Information
Indication: ORACEA® is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA should not be used to treat or prevent infections. ORACEA should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA treatment beyond 16 weeks and safety beyond 9 months have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.